What is Nintx?
Nintx specializes in harnessing the power of plant-based natural products to develop multi-target therapies. The company's core focus lies in modulating the human biological targets and the gut microbiome, addressing multifactorial diseases. By leveraging advanced technologies and fostering strategic partnerships with research institutions and private entities, Nintx aims to enhance its research and development pipeline, which includes both pharmaceuticals and nutraceuticals. Their approach is rooted in understanding the intricate relationships between plants, microorganisms, and human health.
How much funding has Nintx raised?
Nintx has raised a total of $10M across 1 funding round:
Series A
$10M
Series A (2024): $10M with participation from Prefeitura Municipal de Pitanga, Laboratório Tiaraju, MOV Investimentos, Ecoa Capital, and Grupo Adeste
Key Investors in Nintx
Prefeitura Municipal de Pitanga
Prefeitura Municipal de Pitanga is a government entity that likely supports local innovation and economic development initiatives within its jurisdiction.
Laboratório Tiaraju
Laboratório Tiaraju, with its extensive experience in natural products, brings expertise in health and well-being solutions, potentially aligning with Nintx's focus on plant-based therapies.
MOV Investimentos
MOV Investimentos is an impact investment firm focused on supporting innovative companies that aim to reduce social inequalities and environmental degradation, suggesting a strategic alignment with Nintx's mission-driven approach.
What's next for Nintx?
The recent major enterprise-level funding positions Nintx for significant scaling and further development of its therapeutic pipeline. This strategic investment, particularly from entities like MOV Investimentos and Ecoa Capital, suggests a strong validation of Nintx's innovative approach to microbiome and plant-based therapies. The capital will likely be deployed to expand research capabilities, advance clinical trials, and potentially broaden market reach. The company's focus on multifactorial diseases and the gut microbiome aligns with growing global health trends, indicating a promising trajectory for future growth and impact.
See full Nintx company page
